Wells Fargo & Company Impel Pharmaceuticals Inc Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.31 - $1.75 $5 - $29	-17 Reduced 22.97%	57 $0
Q2 2023 Aug 15, 2023	BUY	$1.08 - $2.75 $3 - $8	3 Added 4.23%	74 $0
Q1 2023 May 12, 2023	BUY	$0.96 - $4.1 $0 - $4	1 Added 1.43%	71 $0
Q4 2022 Feb 13, 2023	BUY	$2.59 - $4.0 $10 - $16	4 Added 6.06%	70 $0
Q3 2022 Nov 14, 2022	BUY	$5.78 - $9.32 $138 - $223	24 Added 57.14%	66 $0

Q2 2022 Aug 12, 2022	SELL	$5.83 - $10.12 $162,662 - $282,358	-27,901 Reduced 99.85%	42 $0
Q1 2022 May 16, 2022	BUY	$5.86 - $9.85 $3,767 - $6,333	643 Added 2.36%	27,943 $178,000
Q4 2021 Feb 14, 2022	SELL	$8.33 - $12.14 $165,317 - $240,930	-19,846 Reduced 42.09%	27,300 $236,000
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $395,083 - $1.23 Million	47,146 New	47,146 $574,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.